𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate

✍ Scribed by Punit H. Marathe; Amrita V. Kamath; Yueping Zhang; Celia D’Arienzo; Rajeev Bhide; Joseph Fargnoli

Publisher
Springer
Year
2009
Tongue
English
Weight
373 KB
Volume
65
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The 14C, 13C, and 15N syntheses of a pot
The 14C, 13C, and 15N syntheses of a potent VEGFR-2 kinase inhibitor, Brivanib, and its prodrug, Brivanib Alaninate
✍ Scott B. Tran; Michael W. Lago; Yuan Tian; Sharon X. Gong; Indu Batra; Alban J. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 211 KB

## Abstract The interruption of tyrosine kinase vascular endothelial growth factor receptor‐2 (VEGFR‐2) signaling by the binding of a small molecule inhibitor, for example, Brivanib, to VEGFR‐2 kinase domain has been shown as an effective method of slowing angiogenesis and tumor progression. [^14^C

Preclinical pharmacokinetics and in vitr
Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2
✍ Punit Marathe; Yuwei Tang; Bogdan Sleczka; David Rodrigues; Ashvinikumar Gavai; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

BMS-690514, a potent inhibitor of human epidermal growth factor receptor (HER) 1 (EGFR), 2, and 4, and vascular endothelial growth factor receptors (VEGFR) 1-3, is currently under investigation as an oral agent for the treatment of solid tumors. In vitro and in vivo studies were conducted to charact